CombiMatrix Shares Spike 20 Percent | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Shares of CombiMatrix today jumped as much as 20 percent today on Nasdaq.

By late afternoon, the company's stock had gone as high as $3.88 per share as more than 37,000 shares were traded, more than four times CombiMatrix's average daily volume of 9,029 shares during the past three months.

At the close of the market on Thursday, CombiMatrix shares were up almost 16 percent to $3.73. Nearly 41,000 shares exchanged hands.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.